-
Je něco špatně v tomto záznamu ?
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
JR. Petrie, SP. Marso, SC. Bain, E. Franek, S. Jacob, L. Masmiquel, LA. Leiter, M. Haluzik, I. Satman, M. Omar, M. Shestakova, L. Van Gaal, JF. Mann, FM. Baeres, B. Zinman, NR. Poulter, . ,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie
- MeSH
- antihypertenziva terapeutické užití MeSH
- diabetes mellitus 2. typu komplikace farmakoterapie patofyziologie MeSH
- dvojitá slepá metoda MeSH
- hypertenze komplikace farmakoterapie patofyziologie MeSH
- hypoglykemika terapeutické užití MeSH
- krevní tlak MeSH
- lidé středního věku MeSH
- lidé MeSH
- liraglutid škodlivé účinky terapeutické užití MeSH
- receptor pro glukagonu podobný peptid 1 antagonisté a inhibitory MeSH
- rizikové faktory MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Severní Amerika MeSH
OBJECTIVE: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. METHODS: We analyzed baseline data from LEADER (NCT01179048), an ongoing phase 3B, randomized, double-blind, placebo-controlled cardiovascular outcomes trial examining the cardiovascular safety of the glucagon-like peptide-1 receptor agonist liraglutide in 9340 people with T2DM from 32 countries [age (all mean ± SD) 64 ± 7.2 years, BMI 32.5 ± 6.3 kg/m, duration of diabetes 12.7 ± 8.0 years], all of whom were at high risk for cardiovascular disease (CVD). RESULTS: A total of 81% (n = 7592) of participants had prior CVD and 90% (n = 8408) had a prior history of hypertension. Despite prescription of multiple antihypertensive agents at baseline, only 51% were treated to a target BP of less than 140/85 mmHg and only 26% to the recommended baseline BP target of less than 130/80 mmHg. In univariate analyses, those with prior CVD were prescribed more agents (P < 0.001) and had lower BP than those without (137 ± 18.8/78 ± 10.6 mmHg versus 140 ± 17.7/80 ± 9.9 mmHg; P < 0.001). In logistic regression analyses, residency in North America (64% treated to <140/85 mmHg; 38% treated to <130/80 mmHg) was the strongest predictor of BP control. CONCLUSION: These contemporary data confirm that BP remains insufficiently controlled in a large proportion of individuals with T2DM at high cardiovascular risk, particularly outside North America. Longitudinal data from the LEADER trial may provide further insights into BP control in relation to cardiovascular outcomes in this condition.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031854
- 003
- CZ-PrNML
- 005
- 20171026124248.0
- 007
- ta
- 008
- 171025s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HJH.0000000000000890 $2 doi
- 035 __
- $a (PubMed)26855018
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Petrie, John R $u aInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK bDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA cInstitute of Life Science, College of Medicine, Swansea University Medical School, Swansea, UK dMossakowski Medical Research Centre, Polish Academy of Sciences eDepartment of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSW, Warsaw, Poland fKardio Metabolischen Instituts, Villingen-Schwenningen, Germany gEndocrinology and Nutrition Department, Hospital Son Llàtzer, University Institute of Health Science Research (IUNICS)-Universitat de les Illes Balears, Palma de Mallorca, Spain hDivisions of Endocrinology & Metabolism, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Ontario, Canada i1st Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic jDivision of Endocrinology and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey kDepartment of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu Natal, South Africa lEndocrinology Research Centre, Diabetes Institute mI.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation nFaculty of Medicine, Antwerp University Hospital, Antwerp, Belgium oDepartment of Nephrology, Hypertension & Rheumatology, Friedrich Alexander University of Erlangen, Munchen, Germany pNovo Nordisk, A/S, Bagsvaerd, Denmark qLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada rInternational Centre for Circulatory Health, Imperial College London, London, UK.
- 245 10
- $a LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial / $c JR. Petrie, SP. Marso, SC. Bain, E. Franek, S. Jacob, L. Masmiquel, LA. Leiter, M. Haluzik, I. Satman, M. Omar, M. Shestakova, L. Van Gaal, JF. Mann, FM. Baeres, B. Zinman, NR. Poulter, . ,
- 520 9_
- $a OBJECTIVE: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. METHODS: We analyzed baseline data from LEADER (NCT01179048), an ongoing phase 3B, randomized, double-blind, placebo-controlled cardiovascular outcomes trial examining the cardiovascular safety of the glucagon-like peptide-1 receptor agonist liraglutide in 9340 people with T2DM from 32 countries [age (all mean ± SD) 64 ± 7.2 years, BMI 32.5 ± 6.3 kg/m, duration of diabetes 12.7 ± 8.0 years], all of whom were at high risk for cardiovascular disease (CVD). RESULTS: A total of 81% (n = 7592) of participants had prior CVD and 90% (n = 8408) had a prior history of hypertension. Despite prescription of multiple antihypertensive agents at baseline, only 51% were treated to a target BP of less than 140/85 mmHg and only 26% to the recommended baseline BP target of less than 130/80 mmHg. In univariate analyses, those with prior CVD were prescribed more agents (P < 0.001) and had lower BP than those without (137 ± 18.8/78 ± 10.6 mmHg versus 140 ± 17.7/80 ± 9.9 mmHg; P < 0.001). In logistic regression analyses, residency in North America (64% treated to <140/85 mmHg; 38% treated to <130/80 mmHg) was the strongest predictor of BP control. CONCLUSION: These contemporary data confirm that BP remains insufficiently controlled in a large proportion of individuals with T2DM at high cardiovascular risk, particularly outside North America. Longitudinal data from the LEADER trial may provide further insights into BP control in relation to cardiovascular outcomes in this condition.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antihypertenziva $x terapeutické užití $7 D000959
- 650 _2
- $a krevní tlak $7 D001794
- 650 _2
- $a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $x patofyziologie $7 D003924
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a receptor pro glukagonu podobný peptid 1 $x antagonisté a inhibitory $7 D000067757
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertenze $x komplikace $x farmakoterapie $x patofyziologie $7 D006973
- 650 _2
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 _2
- $a liraglutid $x škodlivé účinky $x terapeutické užití $7 D000069450
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Severní Amerika $7 D009656
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Marso, Steven P
- 700 1_
- $a Bain, Stephen C
- 700 1_
- $a Franek, Edward
- 700 1_
- $a Jacob, Stephan
- 700 1_
- $a Masmiquel, Luis
- 700 1_
- $a Leiter, Lawrence A
- 700 1_
- $a Haluzik, Martin
- 700 1_
- $a Satman, Ilhan
- 700 1_
- $a Omar, Mohamed
- 700 1_
- $a Shestakova, Marina
- 700 1_
- $a Van Gaal, Luc
- 700 1_
- $a Mann, Johannes F
- 700 1_
- $a Baeres, Florian M M
- 700 1_
- $a Zinman, Bernard
- 700 1_
- $a Poulter, Neil R
- 700 1_
- $a ,
- 773 0_
- $w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 34, č. 6 (2016), s. 1140-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26855018 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171026124331 $b ABA008
- 999 __
- $a ok $b bmc $g 1255447 $s 992881
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 34 $c 6 $d 1140-50 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
- LZP __
- $a Pubmed-20171025